A human aldose reductase-like protein, AKR1B10 in the aldo-keto reductase (AKR) superfamily, was recently identified as a tumor marker of several types of cancer. Tolrestat, an aldose reductase inhibitor (ARI), is known to be the most potent inhibitor of the enzyme. In this study, we compared the inhibitory effects of other ARIs including flavonoids on AKR1B10 and aldose reductase to evaluate their specificity. However, ARIs showed lower inhibitory potency for AKR1B10 than for aldose reductase. In the search for potent and selective inhibitors of AKR1B10 from other drugs used clinically, we found that non-steroidal antiinflammatory N-phenylanthranilic acids, diclofenac and glycyrrhetic acid competitively inhibited AKR1B10, showing K i values of 0.35-2.9 m mM and high selectivity to this enzyme (43-57 fold versus aldose reductase). Molecular docking studies of mefenamic acid and glycyrrhetic acid in the AKR1B10-nicotinamide adenine dinucleotide phosphate (NADP ؉ ؉ ) complex and site-directed mutagenesis of the putative binding residues suggest that the side chain of Val301 and a hydrogen-bonding network among residues Val301, Gln114 and Ser304 are important for determining the inhibitory potency and selectivity of the non-steroidal antiinflammatory drugs. Thus, the potent and selective inhibition may be related to the cancer chemopreventive roles of the drugs, and their structural features may facilitate the design of new anti-cancer agents targeting AKR1B10.
The aldo-keto reductase (AKR) superfamily is a rapidly growing group of reduced nicotinamide adenine dinucleotide phosphate (NAD(P)(H))-dependent oxidoreductases that metabolize carbohydrates, steroids, prostaglandins, and other endogenous aldehydes and ketones, as well as xenobiotic compounds. 1, 2) Among the members of this superfamily, aldose reductase (AR) is most extensively studied, because the human enzyme, named AKR1B1 in the family, is the first enzyme of the polyol pathway metabolizing glucose into sorbitol and implicated in the chronic complications of diabetes such as retinopathy, neuropathy and nephropathy. 3, 4) To prevent/combat diabetes complications arising from undesired activity of this enzyme, a wide range of potential AR inhibitors (ARIs) for human AR were developed. [5] [6] [7] [8] Most inhibitors of AR can be classified into the following three groups: carboxylic acids such as tolrestat and zopolrestat, cyclic imides such as minalrestat and fidarestat, and flavonoids such as quercetin and myricetin. In spite of the rapid progress in identifying potential therapeutic compounds that would specifically bind to and inhibit AR, most compounds identified to date, with exception of epalrestat, are unsuccessful in clinical trials due to adverse side effects. [8] [9] [10] These side effects are attributed to the inability of these compounds to selectively inhibit AR since most of these inhibitors also inhibit human aldehyde reductase (AKR1A1 in the AKR superfamily), 11, 12) which is involved in the reduction of diverse aldehydes and dicarbonyl compounds to the corresponding alcohols. 2, 13) In addition, a human NADPH-dependent AKR that shares high overall amino acid sequence identity (71%) with AR was recently identified, 14, 15) and is named AKR1B10 in the AKR superfamily. AKR1B10 shows similar substrate specificity to AR, except for its inability to reduce aldoses such as glucose and xylose. [15] [16] [17] [18] [19] Thus, in addition to AKR1A1, AKR1B10 is an additional control enzyme for the development of selective drugs targeting human AR with the least side effects.
An outstanding feature of AKR1B10 is its up-regulation in lung and hepatic carcinomas (squamous cell carcinoma and adenocarcinoma), 15, 20) as well as in esophageal, uterine and colorectal cancers, [21] [22] [23] indicating its potential role as a tumor marker. The enzyme is suggested to participate in the cell carcinogenesis and tumor development by detoxifying cytotoxic carbonyls, 16, 24) mediating retinoic acid homeostasis, 18, 25) and regulating cellular fatty acid synthesis and lipid metabolism. 19, 26) Thus, this enzyme is a target for the prevention and treatment of the above types of cancer. In this respect, selective inhibition of AKR1B10 over AR is required for the development of the anti-cancer agents targeting to AKR1B10. Some ARIs (tolrestat and sorbinil), bile acids, plant polyphenols and fibrate derivatives were reported to inhibit AKR1B10. 18, 19, [27] [28] [29] While bile acids and plant polyphenols are highly or moderately selective to AKR1B10 inhibition, the selectivity of the other compounds, except for the ARIs, remains unknown.
In this study, we compared the inhibitory effects of the three classes of ARIs on AKR1B10 and human AR in order to evaluate their selectivity. To find selective inhibitors of ARK1B10 from other drugs used clinically, we also examined the inhibition of the two enzymes by non-steroidal antiinflammatory drugs (NSAIDs) and glycyrrhetic acid (GA), because NSAIDs are effective in the treatment of breast, prostate, lung and colon cancers, 30, 31) and GA when used as a NSAID inhibits liver carcinogenesis and tumor growth. 32, 33) Among the drugs, the N-phenylanthranilic acids, diclofenac and GA showed potent and selective inhibition of AKR1B10. The structural base responsible for the high inhibitory potency and selectivity of drugs for AKR1B10 was investigated by comparing the docked models of the NSAIDs in the AKR1B10-NADP ϩ complex and site-directed mutagenesis studies of the residues in the inhibitor-binding site of the enzyme.
MATERIALS AND METHODS

Preparation of Recombinant Enzymes
Recombinant human AR, 34) wild-type AKR1B10 with the N-terminal 6-His tag, 19) and its mutant forms (Q114T, V301L, Q303S and S304A) 29) were expressed in Escherichia coli BL21 (DE3) pLysS cells transformed with expression plasmids harboring their cDNAs, and purified to homogeneity as described previously. The K125L mutant enzyme of AKR1B10 was prepared by site-directed mutagenesis 29) using a sense primer (5Ј-gaccttttccccttagatgataaagg-3Ј) and the corresponding antisense primer, expressed in the E. coli cells, and purified to homogeneity as described above.
Assay of Enzyme Activity The reductase and dehydrogenase activities of AKR1B10 and AR were determined at 25°C by measuring the rate of change in NADPH absorbance (at 340 nm) and fluorescence (at 455 nm with an excitation wavelength of 340 nm), respectively.
19) The IC 50 values for inhibitors were determined in the reaction mixture consisted of 0.1 M potassium phosphate, pH 7.4, 0.1 mM NADPH, 0.2 mM pyridine-3-aldehyde (approximately 15ϫK m concentration) and enzyme in a total volume of 2.0 ml. Kinetic studies in the presence of inhibitors were carried out in both pyridine-3-aldehyde reduction and NADP ϩ -linked geraniol oxidation over a range of five substrate concentrations (0.2-5ϫK m ) at a saturating concentration of coenzyme, and vice versa. The IC 50 and K i values are expressed as the means of at least three determinations.
Molecular Modeling and Energy Minimization
The coordinates for AKR1B10 (PDB code 1ZUA) 35) were obtained from the RCSB Protein Data Bank. The structure was prepared using the Maestro (Schrödinger, LLC) software package Version 8.5 as described previously. 19) In order to eliminate any bond length and bond angle biases from the crystal structure, the ligand, mefenamic acid or GA, was subjected to a full minimization prior to the docking. The docking calculations were performed using the program Glide 5.0 36) on a Linux workstation under the conditions described previously. 19) Figures were generated using PyMOL (DeLano Scientific, Palo Alto, CA, U.S.A.).
RESULTS AND DISCUSSION
Inhibitory Potency and Selectivity of ARIs and
NSAIDs Compounds belonging to the three classes of ARIs, namely, the carboxylic acids, cyclic imides and flavonoids were tested for activity against AKR1B10 (Table  1) . Among the carboxylic acids, tolrestat was the most potent inhibitor, showing lower IC 50 values by one-order magnitude. The inhibitions by the cyclic imides were less potent, and particularly fidarestat showed the highest IC 50 value. The high inhibitory potency of tolrestat is in agreement with the previous reports determined under different assay conditions.
18 ) The results indicate that the inhibitory potency is different depending on the chemical structures even within the same class of ARIs. In contrast, the natural ARIs, flavonoids, similarly inhibited the enzyme activity, but their IC 50 values were higher than those for the synthetic carboxylic acids ARIs. When the inhibitory potencies of the ARIs against AKR1B10 were compared with those against human AR under the same assay conditions, all ARIs inhibited human AR more potently than AKR1B10, and the ARIs, except for fidarestat, showed low selectivity towards AR, ranging from 4 to 33 fold versus AKR1B10. Tolrestat is demonstrated to bind to the active site of AKR1B10 by crystallographic and kinetic studies, 19, 35) in which it competitively inhibits the NADP ϩ -linked geraniol oxidation with respect to the substrate. The inhibition patterns of epalrestat and quercetin for AKR1B10 were also competitive with respect to geraniol (K i values of 0.11Ϯ0.01 and 0.90Ϯ0.06 mM, respectively), suggesting that like tolrestat the ARIs bind to the active site of the enzyme. The low selectivity of most ARIs may result from similarity of the tertiary structures of AKR1B10 and AR including their active sites. 35) Five classes (the indole acetic acids, N-phenylanthranilic acids, phenylacetic acids, arylpropionic acids and GA) of NSAIDs inhibited AKR1B10, and several NSAIDs exhibited inhibitory selectivity to AKR1B10 or human AR ( Table 1) . The indole acetic acids are sulindac and indomethacin, of which sulindac showed the most potent inhibition for AKR1B10, but inhibited AR more potently as previously reported. 37) In contrast, the N-phenylanthranilic acids (flufenamic acid, mefenamic acid and meclofenamic acid), the phenylacetic acid (diclofenac) and GA inhibited AKR1B10 a) The values represent the means of three determinations, whose standard errors were less than 15%. more selectively (more than 43-fold versus AR). The inhibition patterns of sulindac, flufenamic acid, mefenamic acid, meclofenamic acid, diclofenac and GA were all competitive with respect to the alcohol substrate, geraniol (data not shown), showing K i values of 0.27Ϯ0.02, 0.35Ϯ0.04, 0.58Ϯ 0.03, 0.66Ϯ0.07, 1.0Ϯ0.1 and 2.9Ϯ0.1 mM, respectively. The arylpropionic acids (ibuprofen, fenoprofen, flurbiprofen and loxoprofen) showed less inhibitory potency and selectivity for AKR1B10. The other classes of NSAIDs (phenylbutazone, ketotifen and aspirin) and steroidal antiinflammatory agents (dexamethasone and betamethasone) tested in this study showed less than 50% inhibition for AKR1B10 at their 50 mM concentrations.
Residues Responsible for Selective Inhibition by NSAIDs The NSAIDs that showed high selectivity to AKR1B10 were all competitive inhibitors as non-specific ARIs and sulindac. The underlying structural reasons for the high selectivity were examined by constructing the models of docked mefenamic acid and GA in the AKR1B10-NADP ϩ complex (Figs. 1A, B ) based on the crystal structure of the enzyme-NADP ϩ -tolrestat ternary complex. 35) In the models, the two inhibitors occupied the substrate-binding site of the enzyme, but there was a marked difference in their substituents that interact with catalytically important residues (Tyr49 and His111). In the mefenamic acid-bound model, similarly to the side-chain carboxyl group of tolrestat in the crystal structure, 35) its carboxyl group was directed to the side chains of Tyr49 and His111, whereas in the GA-docked model its 3b-hydroxy group, but not C-29 carboxyl group, interacted with the two residues. As the chemical structures of the two inhibitors differ (Fig. 1C) , there were differences in the orientation of the two molecules, which are evident by the residues within 3.5 Å from the inhibitor molecule: Only three (Trp80, Trp112 and Val301) for the mefenamic aciddocked model, in contrast to six (Trp21, Trp112, Phe123, Lys125, Trp220 and Val301) for the GA-docked model. The unique interactions in the GA-docked model are an electrostatic interaction (2.96 Å) between its C-29 carboxyl group and the positively charged side-chain of Lys125, and hydrophobic interactions with the side-chains of Trp21, Phe123 and Trp220. On the contrary, Val301 is one of the common residues that are suggested to be involved in the binding of the two inhibitors, and its main-chain oxygen is involved in a hydrogen-bond network with Gln114 via Ser304.
Among the inhibitor-binding residues predicted by the docked models, Gln114, Lys125, Val301, Gln303 and Ser304 are different from the corresponding residues (Thr, Leu, Leu, Ser and Cys) in human AR. To investigate the participation of the residues in the binding and selectivity of the inhibitors, we prepared mutant AKR1B10s, in which the four residues, except for Ser304, were replaced with the corresponding residues in human AR. Although Ser304 corresponds to Cys in human AR, it was replaced by Ala to remove its possible interaction with Gln114 and/or Val301. The effects of the mutations on the K i values for flufenamic acid, mefenamic acid, diclofenac and GA are summarized in Table 2 . With exception of the Q303S mutation, other mutations decreased the affinity for any of the four drugs by more than 1.6-fold compared to the wild-type enzyme. The V301L mutation resulted in a decrease in the affinity of the drugs by more than 3-fold, suggesting the importance of Val301 for the binding and inhibition selectivity of the drugs. The decrease in the affinity for the drugs by the Q114T mutation ranged from 2.4 to 5.6 fold, although the effects of the S304A mutation were relatively low. The results supported the modelling prediction of the hydrogen-bonding network among Gln114, Ser304 and Val301 shown in Fig. 1 . The same hydrogen-bonding network is observed in the crystal structure of AKR1B10-NADP ϩ -tolrestat complex, 35) while the side-chain of Gln114 is directly involved in the binding of bisdemethoxycurcumin. 19) Thus, the role of the hydrogen-bonding network in inhibitor binding may be different depending on the inhibitors. The mutation of K125L increased only the K i value for GA, supporting the electrostatic interaction between the positively charged side-chain of Lys125 and the C-29 carboxylate of this drug (Fig. 1B) . This interaction, together 888 Vol. 33, No. 5 with the hydrophobic interaction via Val301, is likely to contribute to the high selective inhibition of AKR1B10 by GA.
NSAIDs have potential roles as anticancer drugs, 31, 32) and their long-term use reduce the risk of several cancers. [38] [39] [40] It is believed that these beneficial effects are mediated mainly through inhibition of cyclooxygenase-2, but mechanisms through other target proteins independent on cyclooxygenases have been proposed. 31, 32, 41) Recently, a member of the AKR superfamily, AKR1C3, is reported to be such a target. AKR1C3 stimulates proliferation of breast cancer cells by metabolizing ligands of receptors for steroid hormones and prostaglandins, 42, 43) and is inhibited by sulindac, diclofenac and N-phenylanthranilic acids (flufenamic acid, mefenamic acid and meclofenamic acid), [44] [45] [46] [47] which are identified as potent inhibitors of AKR1B10 in this study. The IC 50 or K i values for the NSAIDs determined with AKR1B10 are comparable to or lower than the values reported with AKR1C3. GA, another selective inhibitor of AKR1B10 found in this study, is less potent against AKR1C3. 47) In addition, the maximum blood concentrations of orally administered flufenamic acid (200-600 mg) and mefenamic acid (250-500 mg), 48) meclofenamic acid (100 mg) 49) and diclofenac (50 mg) 50) are reported to be 14-42, 21-41, 6 and 12 mM, respectively, which are higher than the K i values for the NSAIDs. The potent inhibition of AKR1B10 by the NSAIDs and GA may contribute to their chemopreventive actions against cancers, in which the enzyme is highly expressed.
In conclusion, the present search for the tumor-marker AKR1B10 inhibitors targeting clinically used drugs reveals that this enzyme is potently and selectively inhibited by the N-phenylanthranilic acids, diclofenac and GA with antitumor actions. Our data raise the intriguing possibility that the enzyme's inhibition by the NSAIDs is a novel mechanism of their anti-tumor actions. In addition, structural knowledge of the type of interactions between the enzyme and inhibitors suggested by molecular docking and site-directed mutagenesis analyses can be used to design compounds that are tailored to selectively inhibit AKR1B10. a) The inhibition patterns of the NSAIDs in the NADP ϩ -linked geraniol dehydrogenase were all competitive with respect to the substrate. Mu/Wt represents the ratio of the K i value for the mutant enzyme to that for wild type enzyme.
